This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Medtronic (MDT) in Q1 Earnings?
by Zacks Equity Research
Going by the industry-wide macro trend, we expect Medtronic (MDT) to once again report an adverse effect related to the global supply chain issues in fiscal Q1.
Earnings Preview: Medtronic (MDT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Item 9 Labs Corp. (INLB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Item 9 Labs Corp. (INLB) delivered earnings and revenue surprises of -100% and 29.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Stock Moves 0.4%: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $95.20 in the latest trading session, marking a +0.4% move from the prior day.
Rapid Micro Biosystems, Inc. (RPID) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rapid Micro Biosystems, Inc. (RPID) delivered earnings and revenue surprises of 11.43% and 24.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zevia (ZVIA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevia (ZVIA) delivered earnings and revenue surprises of -55.56% and 7.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
PetIQ (PETQ) Q2 Earnings Top Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 50% and 2.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $93.58 in the latest trading session, marking a +0.32% move from the prior day.
Q2 Earnings Scorecard and Analyst Reports for Visa, Comcast & Medtronic
by Sheraz Mian
Today's Research Daily features updated earnings scorecard and fresh analyst reports on Visa (V), Comcast (CMCSA), Medtronic (MDT) & others.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 5.62% and 64.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed at $93.08 in the latest trading session, marking a +0.61% move from the prior day.
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $91.90, marking a +1.27% move from the previous day.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $89.23, moving -1.22% from the previous trading session.
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $87.51, moving -0.46% from the previous trading session.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Medtronic (MDT) closed at $89.50, marking a -0.13% move from the previous day.
Medtronic (MDT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $90.42, moving +1.37% from the previous trading session.
Medtronic's (MDT) New JV With DaVita to Expand Renal Care Line
by Zacks Equity Research
NewCo is expected to operate successfully, leveraging Medtronic's (MDT) capabilities as a healthcare technology leader and DaVita's deep expertise as a comprehensive kidney care provider.
Company News for May 27, 2022
by Zacks Equity Research
Companies In The News Are: NVDA, AVGO, MDT, SNOW.
Medtronic's (MDT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
On a positive note, Medtronic (MDT) registers organic growth in the Cardiovascular and Neuroscience segments.
Medtronic (MDT) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of -2.56% and 3.85%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Medtronic (MDT) in Q4 Earnings?
by Zacks Equity Research
Medtronic's (MDT) Cardiovascular business is expected to have gained share in both high and low power devices in Q4.
Medtronic (MDT) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Medtronic (MDT) closed the most recent trading day at $102.75, moving -0.79% from the previous trading session.
Medtronic (MDT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Medtronic (MDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Stock Reports for Alibaba, McDonald's & Advanced Micro Devices
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), McDonald's Corporation (MCD), and Advanced Micro Devices, Inc. (AMD).